CEA and Proteus, Immuno’line™ for evaluating the immunogenicity of therapeutic proteins

Nimes, France, Sept 26, 2007 - Protéus announces the launching of "Immuno'line™", a new range of services which is marketed by its PSI (Proteus Services for Industry) division..Immuno'Line™ offers to the pharmaceutical industry new tools to evaluate the risks that a therapeutic protein candidate would induce an immune response and to determine the epitopes associated with such immunogenicity...This technology has been developed by CEA-DSV (French Commission for Atomic Energy – Life Science Division) thanks to the expertise of its department of protein engineering (Institute of Biology and Technologies - IBITECs based in Saclay)... Proteus' Press Release -

Stentys, Stentys Bifurcated Drug-Eluting Stent

PARIS-Sept. 24, 2007--Stentys announced today that its bifurcated stent was successfully implanted yesterday into a 56-year-old male patient at the HELIOS Klinikum Siegburg in Siegburg, Germany.Stentys has developed the world's first next-generation dedicated drug-eluting stent for treatment of blocked coronary artery bifurcations so that hundreds of thousands of patients might avoid open-chest surgery.... Stentys' Press Release [PDF] -

FraBioPosition, the blog dedicated to the french biotech

The aim of the Blog "FraBioPosition" is to share information found in the french life sciences companies websites which could be interesting to follow : new medical devices, pharmaceuticals, treatments, clinical trials...